API Holdings' proposed 100% acquisition of Medlife gets CCI's approval

The deal pertains to the proposed acquisition of 100 per cent equity shares of Medlife by API Holdings.
The Competition Commission of India (CCI) on Wednesday approved the proposed combination of Medlife and API Holdings.

The deal pertains to the proposed acquisition of 100 per cent equity shares of Medlife by API Holdings. Medlife shareholders are to get up to 19.59 per cent equity share capital of API Holdings. 

Medlife is a healthcare company is primarily engaged in wholesale and distribution of drugs, while API Holdings is the parent entity of API Holdings group.

"CCI approves proposed combination of Medlife & API Holdings," the fair trade regulator said in a tweet. API Holdings is the parent of online pharma entity PharmEasy.

In June, a composite scheme of amalgamation filed by API Holdings had been approved by the National Company Law Tribunal (NCLT).

The rehgulator had on Tuesday approved the proposed merger of e-pharmacy companies Medlife and PharmEasy, a month after Medlife made a formal filing to merge with the Temasek-backed company. 

Medlife, a Patna-based company, was valued at $375 million as of January 31, 2020.

(More details awaited)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel